Janssen Pharmaceutica Nv

Jian Liu

Mark R Player

Raymond Joseph Patch

Wing S Cheung

Sharmila Patel

Carl R Illig

William H Parsons

Scott L Dax

Mark James Wall

Mark Andrew Youngman

Sanath K Meegalla

Jinsheng Chen

Guozhang Xu

Gilles C Bignan

Micheal D Gaul

Kenneth M Wells

Hui Huang

Bao-Ping Zhao

Michele C Jetter

Raul R Calvo

Wenxi Pan

Davoud Asgari

Xun Li

Yu-Kai Lee

Michael Richard Brandt

Derek A Beauchamp

Huaping Hu

Raul L Calvo

Michael Brandt

The present invention relates to compounds of Formula (I), methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating a condition including but not limited to ankylosing spondylitis, artherosclerosis, arthritis (such as rheumatoid arthritis, infectious arthritis, childhood arthritis, psoriatic arthritis, reactive arthritis), bone-related diseases (including those related to bone formation), breast cancer (including those unresponsive to anti-estrogen therapy), cardiovascular disorders, cartilage-related disease (such as cartilage injury/loss, cartilage degeneration, and those related to cartilage formation), chondrodysplasia, chondrosarcoma, chronic back injury, chronic bronchitis, chronic inflammatory airway disease, chronic obstructive pulmonary disease, diabetes, disorders of energy homeostasis, gout, pseudogout, lipid disorders, metabolic syndrome, multiple myeloma, obesity, osteoarthritis, osteogenesis imperfecta, osteolytic bone metastasis, osteomalacia, osteoporosis, Paget's disease, periodontal disease, polymyalgia rheumatica, Reiter's syndrome, repetitive stress injury, hyperglycemia, elevated blood glucose level, and insulin resistance.

Substituted thiazolidinedione indazoles, indoles and benzotriazoles as estrogen-related receptor-&#x3b1; modulators

The invention is directed to compounds of Formula (I): to pharmaceutical compositions containing such compounds and to methods of treatment using them.

Benzimidazole modulators of VR1

The invention is directed to compounds of Formula I: wherein Q, Y, A are set forth in the specification, as well as solvates, hydrates, tautomers or pharmaceutically acceptable salts thereof, that inhibit protein kinases, especially Aurora-1, Aurora-2 and Aurora-3 kinases.

[object Object]

The invention is directed to compounds of Formulae I and II: wherein R, R, R, R, R, Y, Y, Y, Yand X are set forth in the specification, as well as solvates, hydrates, tautomers or pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase.

Quinolinone derivatives as inhibitors of c-fms kinase

Growing community of inventors

Manalapan, NJ, United States of America

Jian Liu